Despite uncertainty and concern buffeting Massachusetts hospitals, the state’s largest health system saw its finances improve ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

WASHINGTON — Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump ...

A vaccine adviser at the CDC with ties to health secretary Robert F. Kennedy Jr. is being given a new portfolio overseeing ...

With its vaccine schedule, “Denmark has made a values choice to accept preventable hospitalizations and illnesses that other ...

Nine drugmakers are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the ...

UnitedHealth Group said Friday that the consultants it hired to audit its operations found they’re not only “robust,” but ...

STAT is leading the way in covering the Trump administration’s changes in health care and medicine because our journalists ...

BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.

An FDA program to fast-track drug reviews has become a way for the White House to influence which medicines make their way fastest to patients ...

BioMarin said it is acquiring Amicus Therapeutics, maker of rare-disease drugs, for $4.8 billion. A new FDA program meant to ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...